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Type I ovarian tumors, where precursor lesions in the ovary have clearly been described, include endometrioid, clear cell, mucinous,
low grade serous, and transitional cell carcinomas, while type II tumors, where such lesions have not been described clearly
and tumors may develop de novo from the tubal and/or ovarian surface epithelium, comprise high grade serous carcinomas,
undifferentiated carcinomas, and carcinosarcomas. The carcinogenesis of endometrioid and clear cell carcinoma (CCC) arising
from endometriotic cysts is significantly influenced by the free iron concentration, which is associated with cancer development
through the induction of persistent oxidative stress. A subset ofmucinous carcinomas develop in associationwith ovarian teratomas;
however, the majority of these tumors do not harbor any teratomatous component. Other theories of their origin include mucinous
metaplasia of surface epithelial inclusions, endometriosis, and Brenner tumors. Low grade serous carcinomas are thought to evolve
in a stepwise fashion from benign serous cystadenoma to a serous borderline tumor (SBT). With regard to high grade serous
carcinoma, the serous tubal intraepithelial carcinomas (STICs) of the junction of the fallopian tube epitheliumwith themesothelium
of the tubal serosa, termed the “tubal peritoneal junction” (TPJ), undergo malignant transformation due to their location, and
metastasize to the nearby ovary and surrounding pelvic peritoneum. Other theories of their origin include the ovarian hilum cells.
1. Introduction
Ovarian carcinoma is the most lethal gynecological malig-
nancy. It is estimated that there will be >140000 deaths per
year worldwide [1]. Although many surgical techniques and
chemotherapies have been developed for ovarian carcinoma,
the prognosis remains poor, with a five-year survival rate of
45% [2]. Although the prognosis is more favorable in patients
with stage I/II tumors, the majority of patients present with
advanced stage disease (III/IV).
Most ovarian carcinomas have been suggested to orig-
inate from the ovarian surface epithelium or postovulatory
inclusion cysts formed after follicular rupture and repair [3,
4]. Factors associated with a lower risk of developing ovarian
cancer include pregnancies, the use of oral contraceptives,
breast feeding, tubal ligation, and hysterectomy [5]. As of
these factors are all associated with reduced numbers of ovu-
lations, and it is believed that an increased lifetime number
of ovulations play a significant role in the development of
ovarian cancer [6].
According to the incessant ovulation hypothesis, every
ovulation creates a wound, and the surface ovarian epithelial
cells are then repaired by increased proliferation. This may
increase the likelihood for DNA damage and carcinogenic
mutations [5]. However, this hypothesis is inconsistent with
the observation that patients with polycystic ovarian syn-
drome who have decreased ovulatory cycles appear to have
an increased ovarian cancer risk [7]. The increased risk of
ovarian cancer after the use of infertility drugs supports the
fact that stimulation of the ovarian surface epithelium with
gonadotropins increases the risk of ovarian cancer develop-
ment [3, 8, 9]. The hypothesis regarding the gonadotropin-
based stimulation is supported by the fact that the ovar-
ian cancer incidence increases after menopause, when the
gonadotropin levels rise [3, 10, 11].
Ovarian carcinomas have been classified according to
the different epithelia of the reproductive female tract. The
tumors are divided into serous, mucinous, endometrioid,
clear cell, and transitional cell carcinomas. It has traditionally
been thought that ovarian carcinomas are derived from
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the ovarian surface epithelium and that subsequent metapla-
sia leads to the development of the various cell types (serous,
mucinous, endometrioid, clear cell, and transitional) which
constitute the morphological subtypes of ovarian epithelial
carcinomas. However, new histopathological, molecular, and
genetic studies have recently provided a better model for
ovarian carcinogenesis, showing two broad categories, which
are designated as type I, where precursor lesions in the ovary
have clearly been described, and type II, where such lesions
have not been described clearly and tumors may develop
de novo from the tubal and/or ovarian surface epithelium
[4, 12]. Type I tumors include low grade serous, mucinous,
endometrioid, clear cell, and transitional cell carcinomas,
while type II tumors comprise high grade serous carcinomas,
undifferentiated carcinomas, and carcinosarcomas.
Type I tumors are suggested to behave in an indolent
behavior and appear to form part of a morphological and
molecular continuum starting with cystadenoma/adenofi-
broma benign tumors that subsequently develop towards
atypical proliferative or borderline tumors and then finally
towards invasive tumors.They are often confined to the ovary
at the time of diagnosis, with a stable genome and without
TP53 mutations, although somatic mutations are frequently
detected in a number of genes [13]. Each morphological
subtype exhibits a distinctive molecular profile characterized
by mutations targeting specific cell signaling pathways. Even
though clear cell carcinoma is listed as a type I tumor, it may
actually belong to an intermediate category because of its
mutations and behavior.
Type II tumors are suggested to be more aggressive, are
found at advanced stage, and are genetically highly unstable;
the majority have TP53 mutations, and almost half of the
cases have mutation, hypermethylation, or dysfunction of
breast cancer gene (BRCA) 1/2 [14–17]. Several lines of
evidence now indicate that these tumors may originate from
the epithelium of the fimbrial portion of the fallopian tube
[18–21] and/or the ovarian surface epithelium.
2. Type I
2.1. Endometrioid Carcinoma and Clear Cell Carcinoma.
The recent study followed a cohort of 6398 women with
clinically documented endometrioma and evaluated the risk
of ovarian cancer based on the varying time periods from
diagnosis of endometriosis [22]. During the follow-up of
up to 17 years, 46 (0.7%) incidental ovarian cancers were
identified, translating into a standardized incidence ratios of
13.2. This risk increased with age, with an incidence ratio of
13.2 in patients over 50 years old. In the malignant trans-
formation cases of endometriotic cyst, serial transvaginal
ultrasonography (USG) examinations revealed an increase
in its size [23]. A review of 29 studies published from 1973
to 2002 on the prevalence of endometriosis in epithelial
ovarian cancers organized by location of disease examined
the different histologic subtypes with endometriosis in the
same ovary. It was found that there was a prevalence of
4.5% in serous, 1.4% in mucinous, 35.9% in clear cell, and
19% in endometrioid carcinomas [24]. There is increasing
evidence that clear cell and endometrioid carcinomas can
arise from endometriosis. The specific correlation between
endometriosis and ovarian malignancy and their epidemio-
logical patterns have been studied. For both endometriosis
and ovarian carcinoma, increased risks were associated with
infertility, early menarche, late menopause, and nulliparity,
and the protective factors were tubal ligation, hysterectomy,
the use of oral contraceptives, and pregnancy [25].
Molecular aberrations that are characteristics of inflam-
matory processes in endometriosis may contribute a
number of survival and growth signals to the malignant
transformation of the ovarian surface epithelium. Endomet-
riosis at the ovary confers an imbalance in the cytokinemilieu
(interleukin-1, interleukin-6, and interleukin-8) inducing
surges of immunomodulatory and growth-stimulating
cytokines (e.g., tumor necrosis factor- (TNF-) alpha) similar
to those observed in ovarian malignancy. Endometriosis
also drastically changes the hormonal milieu and generates
growth factor (such as insulin-like growth factor (IGF)) to
which ovarian cancer cells have demonstrated dependency
[24]. The propensity of endometriotic cells to expand
clonally, as a result of intrinsic anomalies and advanced
inflammation in endometriosis, generates a constitutive
abundant flux of several stimulatory signals, which induces
progressive transcriptional changes that drive sustained
proliferation. This also increases the rate of DNA repair and
the likelihood of accumulation of mutations in these cells.
Mutations of the phosphatase and tensin homolog deleted
from chromosome 10 (PTEN) tumor suppressor are fre-
quently found in ovarian endometrioid carcinomas [26]. The
identification of PTEN mutations in endometriotic lesions
(20.6%) adjacent to ovarian endometrioid (20%) and clear
cell carcinomas (8.3%) supports the notion that endometrio-
sis is a precursor lesion for endometrioid and clear cell
carcinomas [27]. In a mouse model of endometrioid ovarian
carcinoma, PTEN deletion on the background of oncogenic
K-RAS activation within the ovarian surface epithelium gave
rise to endometriotic-like precursor lesions which developed
into invasive endometrioid ovarian carcinoma within seven
to twelve weeks [28]. These results indicate that expression
of oncogenic K-RAS and inactivation of the PTEN tumor
suppressor gene is an early event in the development of
endometrioid carcinoma. Pathologically, the coexistence of
ovarian carcinoma and endometriosis is frequently observed,
with the latter called “atypical endometriosis,” which is a
putative precursor lesion including atypia of cell nucleus [29].
The overexpression of hepatocyte nuclear factor-1
(HNF-1) beta [30] and mutations of the ARID1A gene [31]
are also found in some atypical endometriosis adjacent to the
carcinoma. Furthermore, the histogenesis of endometrioid
carcinoma could arise from endometriosis, which originates
from HNF-1 beta-negative inclusion cyst cells. In contrast,
the expression ofHNF-1 beta could be associatedwith the late
secretory or menstrual phase endometrial-endometriosis—
clear cell carcinoma (CCC) lineage, which means that CCC
could arise from the HNF-1 beta—positive epithelial cells
associated with endometriosis [32]. HNF-1 beta promotes
aerobic glycolysis, which may contribute to cell survival
under hypoxic conditions.The overexpression of HNF-1 beta
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may also play a role in the occurrence of CCC in stressful
environment [33].
It has recently been recognized that carcinogenesis
of endometrioid and clear cell carcinomas arising from
endometriotic cysts is significantly influenced by the
microenvironment in which the tumor arises [34]. As
the content of an endometriotic cyst includes highly
concentrated old blood, the concentration of iron is
markedly high in endometriotic cysts [35]. Free iron is
associated with cancer development through the induction
of persistent oxidative stress. The epithelial cells within the
endometriotic cyst are exposed to extensive oxidative stress
(reactive oxygen species (ROS)) and hypoxia, and, as a result,
they are subjected to more cellular and DNA damage and
have less efficient DNA repair [36, 37].
Ovarian clear cell carcinomas (OCCCs) are rare tumors
in Europe (4%) [38] and theUnited States (5%) [39]; however,
they are common in Japan (20%). OCCCs are commonly
considered to be chemoresistant tumors. Even thoughOCCC
is listed as a type I tumor, it may actually belong to an
intermediate category. Using a microarray dataset of ovarian
cancers, the OCCC signature comprising 437 genes was
identified [40]. Such OCCC signature genes contain many
oxidative stress-related genes, which are actually upregu-
lated by epigenetic mechanism in OCCCs. Therefore, it is
estimated that the OCCC signature is first induced by the
stressful environment in the endometriotic cyst and then
becomes fixed during the course of development of the
OCCC. It has been shown that there is similarity in the gene
expression profile between renal cell carcinomas (RCCCs)
andOCCC [41]. Sorafenib, which has recently been approved
for RCCC, also showed significant antitumor activity in both
of the twoOCCCpatients [42] andmay thus represent a novel
therapeutic agent for OCCC.
Mutations in the beta-catenin gene, CTNNB1, which is
involved in cell proliferation and theWnt pathway, have been
found in up to 30% of endometrioid carcinomas but are
uncommon in other subtypes [43, 44]. This finding suggests
that beta-catenin and dysregulation of the wnt pathway are
important in the development of endometrioid carcinomas.
Furthermore, somatic mutation of the PI3K gene (PIK3CA)
has been reported in 20% of endometrioid and clear cell
carcinomas [45]. A more recent study has reported that
PIK3CAmutations occur only in high grade endometrioid or
high grade CCCs [46]. Microsatellite instability is present in
endometrioid carcinoma and CCC but is only rarely detected
in serous and mucinous tumors [47, 48].
2.2. Mucinous Carcinoma. There are several theories
accounting for the origin of ovarian mucinous carcinoma.
It is well recognized that a subset of mucinous carcinomas
can develop in association with ovarian teratomas;
however, the majority of these tumors do not harbor
any teratomatous component [49, 50]. Other theories
regarding the origin of these tumors include mucinous
metaplasia of surface epithelial inclusions, endometriosis,
and Brenner tumors [23, 50]. However, it is exceedingly
rare to find mucinous metaplasia of the ovarian surface
epithelium or within the lining of cortical inclusion cysts
[51, 52], and there have only been a few case reports of
such findings [53, 54]. Mucinous carcinomas can develop
from endometriosis; however, this observation appears to
be relatively uncommon, except for mu¨llerian endocervical
mucinous or mixed (seromucinous) borderline tumors
[55, 56].
The association between Brenner and mucinous tumors
has been known [57–59]. Amplification of 12q14-21 in both
a mucinous carcinoma and an associated Brenner tumor
was reported recently [60]. Mucinous carcinomas (intestinal
type) and Brenner tumors may share similar histogenesis
from transitional cell (Walthard) nests at the tubal peritoneal
junction (TPJ) [61, 62]. Small mucinous tumors are rarely
diagnosed, possibly because they are thought to be Brenner
tumors with foci of mucinous differentiation [62].
Regardless of the origin of ovarian mucinous carcinoma,
morphological transitions from cystadenoma to a mucinous
borderline tumor (MBT) to intraepithelial carcinoma and
invasive carcinoma have been recognized for some time, and
an increasing frequency of KRASmutations at codons 12 and
13 has been reported in cystadenomas, MBTs and mucinous
carcinomas, respectively [63–66]. Similar to low grade serous
carcinomas, mucinous carcinoma and adjacent MBT and
mucinous cystadenoma show the same KRASmutation, sup-
porting the hypothesis of the “adenoma-carcinoma sequence”
[67, 68] and the view that mucinous carcinomas develop
in a stepwise fashion from mucinous cystadenomas and
MBTs.These findings suggest that KRASmutation is an early
occurrence in the pathogenesis of ovarian mucinous tumors.
Unlike low grade serous carcinomas, BRAFmutations are not
a feature of ovarian mucinous neoplasms of intestinal type.
Most primary ovarian mucinous carcinomas (and bor-
derline tumors) are of the so-called intestinal (enteric or
nonspecific) type, unilateral, and stage 1. Advanced stage
neoplasms (stage 3 or 4) are extremely uncommon. It is
now clear that ovarian mucinous neoplasms associated with
pseudomyxoma peritonei are almost always of vermiform
appendix origin [69, 70]. While many primary ovarian muci-
nous carcinomas contain goblet cells and even occasionally
Paneth or neuroendocrine cells, the presence of goblet cells
is not a prerequisite for an intestinal type mucinous tumor.
In fact, many of these more closely resemble gastric or pan-
creaticobiliary (upper gastrointestinal) mucinous neoplasms
[71].
A much more uncommon mu¨llerian (endocervical)
type of ovarian mucinous carcinoma and borderline tumor
also exists [72, 73]. While borderline mucinous neoplasms
of mu¨llerian type have been well described, malignant
mu¨llerian mucinous tumors are extremely uncommon.
According to several studies, smoking has been found
to be a risk factor associated with benign, borderline, and
mucinous carcinomas [74–76]. It has been speculated that
the relationship between cigarette smoking and the devel-
opment of mucinous tumors could be due to the similarity
of mucinous tumors to the gastrointestinal mucosa. The
latter tumors, such as the stomach and pancreas carcinomas,
have consistently been associated with cigarette smoking
[75].
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2.3. Low Grade Serous Carcinoma. The low grade serous
carcinomas are genetically stable and are characterized by
their low number of genetic mutations. Therefore, they
develop slowly from well-recognized precursors and behave
in an indolent fashion. They are much less common than
high grade serous carcinomas and are thought to evolve in a
stepwise fashion from benign serous cystadenoma to serous
borderline tumors (SBTs) (also referred to as atypical prolifer-
ative serous tumor) andfinally to lowgrade serous carcinoma.
Some authors have also suggested that serous tumors with
micropapillary architecture may represent an intermediate
step between SBTs and low grade serous carcinomas [77–80].
KRAS mutations at codons 12 and 13 occur in one-third of
SBTs [81] and in 33% of low grade serous carcinomas [82].
Similarly, BRAF mutations at codon 599 occur in 28% of
SBTs and 30% of low grade serous carcinomas [81, 83, 84].
Mutations in ERBB2 occur in less than 5% of these tumors.
Mutations of KRAS and BRAF are detected in both SBTs
and cystadenoma epithelium adjacent to SBTs [85]. These
findings suggest that mutations of KRAS and BRAF are very
early events in tumorigenesis, preceding the development of
SBTs. The KRAS, BRAF, and ERBB2 oncogenes are upstream
regulators of mitogen-activated protein kinase (MAPK), and
mutations in these genes result in constitutive activation of
the MAPK signal transduction pathway, which in turn leads
to uncontrolled cell proliferation [17].
In contrast to high grade serous carcinoma, p53 muta-
tions are uncommon in low grade serous carcinoma and
are identified in <10% of these tumors [86]. A methylation
profile distinct from that of high grade serous carcinoma has
been identified in epigenetic studies [87]. Low grade serous
carcinomas have a DNA content and level of copy number
alterations which more closely resembles SBTs than high
grade serous carcinomas and are intermediate between the
two [88, 89]. A recent study involving a whole exome analysis
of low grade serous carcinomas of the ovary identified an
average of only 10 somatic mutations per tumor [90, 91].
In contrast, high grade serous carcinomas are generally
aneuploidy, with a high level of copy number alterations [89].
These carcinomas typically sustain 50–70 somatic mutations,
with TP53 representing a clear driver mutation [92].
Several theories exist to explain the origin of serous
tumors. The traditional concept has been that they were
derived from ovarian epithelial inclusions formed by
invaginated ovarian surface epithelium that has undergone
mu¨llerian metaplasia [52]. It has been postulated that the
native ovarian surface mesothelium possesses the potential
to transform into an epithelial or mesenchymal phenotype in
response to signals such as those associated with ovulation.
The exposure of the mesothelial cells of an inclusion cyst
to the ovarian stromal microenvironment may result in
transformation to mu¨llerian epithelium. However, well-
documented examples of a transition of these cysts to serous
carcinomas are rare.
Another theory is that tumors may be derived from a
secondary mu¨llerian system, thought to represent embry-
ological remnants of the proximal mu¨llerian ducts, located
within the ovarian hilum [93, 94]. These mu¨llerian epithelial
cysts form the serous tumors, and their proliferation induces
subsequent obliteration of the adjacent ovarian parenchyma.
However, SBTs are only rarely reported to occur in the ovarian
hilum [95, 96]. There was a recent theory which suggested
that low grade serous carcinoma may be derived from the
fallopian tube. The theory suggests that shed tubal epithelial
cells can implant on the ovarian surface epithelium, be taken
into inclusion cysts, and transform serous neoplasms, while
implants on other peritoneal surfacesmay account for extrao-
varian endosalpingiosis and noninvasive tumor implants [97,
98]. It is thought that chronic inflammation may induce the
proliferation of the tubal epithelium, from which clusters of
cells can then shed and implant on the ovarian and peri-
toneal surfaces, resulting in SBTs, noninvasive implants, and
endosalpingiosis.
3. Type II
3.1. High Grade Serous Carcinoma. These tumors are high
grade from the start, evolve quickly, and are frequently found
at an advanced stage.At themolecular level, high grade serous
carcinomas show TP53 genemutations in nearly 80% of cases
[14–17] and a highKi67 proliferation index (between 50% and
75%). Overexpression of HER2/neu is also found in 20–67%,
AKT activation in 12–30% and inactivation of p16 in 15% of
cases. In addition, the overexpression of the human leukocyte
antigen-G (HLA-G) system is found in 61%of cases, and there
is overexpression of apolipoprotein E (apoE) in 66% of cases,
but these are rarely found in low grade serous carcinomas.
Chromosomal rearrangements are farmore common in these
types of tumors, probably reflecting the high degree of
associated gene instability. Currently, up to 10–15% of ovarian
carcinomas are believed to be hereditary [99]. Mutations in
the high penetrance gene, BRCA1 and BRCA2, are associated
with 90% of hereditary ovarian carcinoma cases.The lifetime
risk of developing ovarian cancer is approximately 40–
50% for BRCA1 mutation carriers and 20–30% for BRCA2
mutation carriers. Inherited BRCA1 and BRCA2 mutations
predispose females to high grade serous carcinoma of
the ovary.
In 2001, Piek et al. found new transformations on tubal
segments removed from females who had either BRCA
mutations or a strong family history of ovarian carci-
noma who underwent a risk-reducing bilateral salpingo-
oophorectomy (BSO) [18]. Of 12 tubal specimens, six had
areas of cellular dysplasia noted in the tubal epithelium
and five additional specimens had hyperplastic lesions in
the microscopic findings. These dysplastic and hyperplastic
lesions resembled high grade serous carcinoma but without
stromal invasion. These malignancies were found in the
distal tube in 4–17% of females with BRCA mutations at the
time of their risk-reducing surgery, 57% to 100% of which
were located in the distal portion of the tubes [100–104].
Dysplastic lesions within the tubal epithelium are termed
“serous tubal intraepithelial carcinomas (STIC).” In 2003,
Piek et al. hypothesized that hereditary serous carcinomas
might originate from the epithelium of the fallopian tube
which has spilled onto the surface of the ovary or peritoneum
[105].
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A very early abnormality termed “secretory cell out-
growths” (SCOUTs) has recently been reported [106]. This
consists of a succession of at least 30 almost exclusively
secretory epithelial cells with a pseudostratified appearance
[107]. An immunohistochemical analysis can confirm the
diagnosis, which is characterized by a low PTEN and Ki67
index, and, in most cases, there are no TP53 mutations
[106, 108–110]. The TP53 signatures are the next earlier
entities, which have an immunohistochemical definition of
at least 12 consecutive secretory cells that are p53 positive
and have a low proliferative index (Ki67 < 10%). In the
next place, “serous tubal intraepithelial lesions” (STILs) [111]
also called “transitional intraepithelial lesions of the tube”
(TILTs) by some authors have proliferative p53 signatures,
tubal dysplasia, and even tubal epithelial atypia [18, 112].
These have also been described as a group of tubal anomalies
with different p53 signatures compared to STICs [113]. In
the serous carcinogenic sequence, SCOUTs may be able to
evoke in benign lesions expressing p53 (p53 signature) with
a low proliferation index and little genetic instability. Then,
benign lesions expressing p53 would appear (STILs/TILTs),
corresponding to tubal dysplasia lesions, finally culminating
in the appearance of STICs [114]. Rate of the STICswas 59% in
patients with serous tumors [21] and the former was clonally
related to the latter [115]. There were no STICs identified in
mucinous, endometrioid, or carcinosarcoma histology.Thus,
STICs seem to be associated with the development of serous
carcinoma.
It has recently been reported that the junction of the
fallopian tube epithelium with the mesothelium of the
tubal serosa, termed the “TPJ,” might be a potential site of
carcinogenesis, as the role of epithelial junctions, notably
the uterine cervical squamocolumnar, gastroesophageal, and
anorectal junctions, in neoplasia is well recognized [116].
This junction is highly tortuous with tongues of mesothelium
extending from the infundibular peritoneal-fimbrial junction
at the outer edges of the fimbriae, with irregular tongues of
peritoneum extending onto some of the plicae. The extensive
and elaborate lymphovascular system is in almost direct
contact with the basementmembrane of the tubal epithelium,
suggesting that even a minimally invasive carcinoma could
easily invade this system and rapidly spread throughout the
abdominal cavity.
Given that STICs have shorter telomeres than high grade
serous ovarian carcinoma and also have gamma H2AX
overexpression, these results seem to suggest that DNA
repair mechanisms are activated in the early conditions
[117]. Telomere shortening appears to take place in most
human preinvasive epithelial lesions [118]. As a result, some
authors have hypothesized that STICs are not metastases
from ovarian carcinoma (different telomere lengths between
STICs and ovarian carcinomas) but tubal precursor lesions
of ovarian carcinoma [119]. In brief, the small areas of STICs
undergomalignant transformation and, due to their location,
metastasize to the nearby ovary and surrounding pelvic
peritoneum.
On the other hand, serous carcinoma may have a truly
ovarian origin. Our group reviewed the clinical charts
of 543 patients with epithelial ovarian carcinomas who
underwent laparotomy and collected patients whose clinical
and transvaginal ultrasonography (USG) findings for adnexal
regions 12months or fewer prior to the surgery were available
[23]. The data of 35 patients were available (11 serous, 6
mucinous, 8 clear cell, and 10 endometrioid). In their series of
serous carcinomas, there had been no apparent abnormalities
in the adnexal regions, 2 to 12months prior to the diagnosis in
9 of the 11 (82%) patients. Strikingly, 8 of 9 serous carcinoma
patients with no apparent abnormalities at the last visit
presented with stage III tumors and the final pathological
findings after surgery showed that therewere nomalignancies
in adjacent lesions, indicating that serous carcinomas might
develop from the ovaries suddenly and progress very rapidly.
However, their report raises the possibility that there might
be the small malignancy lesion of the fallopian tubes which
was not able to be detected in some cases.
In 1994, Bell and Scully reported 14 cases of incidentally
found microcarcinoma in normal-appearing ovary [120].
Most of them were serous carcinoma, suggesting de novo
carcinogenesis, whereas there were no cases of mucinous
carcinoma. Furthermore, a notable study has recently been
reported, in which the ovarian hilum cells show increased
transformation potential after inactivation of tumor sup-
pressor genes transformation-related protein 53 (Trp53) and
retinoblastoma 1 (Rb1) in mice [121]. These pathways are
altered frequently in the high grade serous carcinoma. In
brief, the ovarian surface epithelium (OSE) at the TPJ
contains a novel stem cell niche that is responsible for OSE
regeneration and is prone tomalignant transformation.These
stem cells in the hilum may have increased transformation
potential after inactivation of Trp 53 and Rb 1 and be the
origin of high grade serous carcinoma.
4. Conclusions
The new model of assigning ovarian epithelial carcinomas
into two groups demands a radical change of current clinical
management. Type I ovarian carcinomas are considered to
arise via a well-defined adenoma-carcinoma sequence from
a benign precursor lesion, such as a borderline tumor or
endometriosis, and to evolve in a stepwise fashion. Type
I carcinomas are, in general, slow growing, indolent neo-
plasms, and like type I endometrial carcinomas. In con-
trast, type II carcinomas are high grade clinically aggressive
neoplasms. Most represent high grade serous carcinoma.
Carcinosarcoma and undifferentiated carcinoma, which are
both predominantly variants of high grade serous carcinoma,
are also included in this category. Type II carcinomas are
often associated with TP53 mutations and are like type II
endometrial carcinomas. There is emerging evidence that
many arise from the epithelium of the distal fallopian tube
and/or ovary.
Clinicopathological features and molecular genetic alter-
ations of two types of ovarian carcinoma are summarized in
Table 1.
We study the carcinogenesis of ovarian carcinoma to
determine the characteristics of each subtype carcinoma and
to optimize the treatment of the disease. For example, there
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Table 1: Summary of clinicopathological features and molecular genetic alterations of two types of ovarian carcinoma.
Type I tumors Type II tumors
Behavior Indolent Aggressive
At the time of the
diagnosis Early stage Advanced stage
Survival rate at 5 years About 55% About 30%
Histological
type/Precursors
















Low grade serous carcinoma/ Serous cystadenoma,Adenofibroma Undifferentiated carcinoma/ ?
Atypical proliferative serous
tumor (SBT) Carcinosarcoma/ ?
Mu¨llerian epithelial cyst
Transitional cell carcinoma/ Brenner tumor
Gene expression
profile
Genetic instability Not very unstable Very unstable
PTEN mutation 15–20% Low
HNF-1 beta
overexpression 90% Low
ARID1A mutation 40–50% Not found




KRAS mutation 30–65% Low
BRAF mutation 30–65% Low
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are similarities in the gene expression between RCCC and
OCCC, as determined using amicroarray analysis. Sorafenib,
which has recently been approved for RCCC, also showed
significant antitumor activity in the patients with recurrent
chemoresistant OCCC. With regard to benign cysts of the
ovary (e.g., endometriotic, serous, andmucinous cysts), there
need to be a unification of the preventive treatment strategy
and to detect an early cancer by careful follow-up with USG
at every 6 months and some bioindices (countermeasures
against type I carcinomas). Complete bilateral salpingo-
oophorectomy as a risk-reducing strategy in patients with
BRCA mutations in an approach is worthy of further
investigation and it may be reasonable to consider bilateral
salpingectomy for all patients undergoing hysterectomy for
benign disease (countermeasures against type II carcinomas).
In other words, we are entering a period of individualized
therapies including preventive therapies, where it is necessary
to know the characteristics of each carcinoma using biomark-
ers and gene profiling. We hope that all type I and type II
carcinomas of the ovary will be able to be prevented and/or
cured completely in the near future.
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